Table 2.
Demographics and clinical characteristics at study entry (time of first local regional therapy)
| Variable | AC (N = 82) |
UNOS-DS (N = 229) |
P-value |
|---|---|---|---|
| Male (%) | 65 (83.3) | 191 (85.3) | .72 |
| Median age (IQR) | 63.7 (58.2–67.5) | 62.6 (58.0–66.6) | .46 |
| Race/ethnicity (%) | .18 | ||
| Caucasian | 48 (58.5) | 130 (57.3) | |
| Hispanic | 14 (17.1) | 56 (24.7) | |
| Asian | 11 (13.4) | 24 (10.6) | |
| African American | 2 (2.4) | 10 (4.4) | |
| Other | 7 (8.5) | 9 (3.1) | |
| Liver disease etiology (%) | .57 | ||
| Hepatitis C | 39 (47.6) | 121 (55.5) | |
| Alcohol | 11 (13.4) | 35 (16.1) | |
| NAFLD | 16 (19.5) | 27 (12.4) | |
| Hepatitis B | 8 (9.8) | 16 (7.3) | |
| Other | 6 (7.3) | 13 (6.0) | |
| > 1 Diagnosis | 2 (2.4) | 6 (2.8) | |
| CTP (%) | .78 | ||
| A | 54 (72.0) | 155 (72.8) | |
| B | 20 (26.7) | 52 (24.4) | |
| C | 1 (1.3) | 6 (2.8) | |
| Median MELD (IQR) | 9 (7–11) | 9 (7–12) | .99 |
| Median AFP (IQR) | 20.2 (6.0–187) | 12.1 (5.0–67.0) | .15 |
| Median # of HCC lesions | 3 (2–4) | 2 (1–2) | <.001 |
| Total tumor diameter (cm; IQR) | 10.0 (8.3–12.9) | 6.2 (5.5–7.1) | <.001 |
Abbreviations: AFP, alpha-fetoprotein; AC, all-comers; CTP, Child-Turcotte-Pugh; HCC, hepatocellular carcinoma; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; UNOS-DS, United Network for Organ Sharing-downstaging.